The IL-1 trap rilonacept resolves and prevents recurrent pericarditis

Nature Reviews Cardiology, Published online: 01 December 2020; doi:10.1038/s41569-020-00491-3In patients with recurrent pericarditis, treatment with rilonacept, an engineered fusion protein that acts as an IL-1 trap, leads to a rapid resolution of recurrent pericarditis episodes and reduces the risk of pericarditis recurrence.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research